Comparative Pharmacology
Head-to-head clinical analysis: FORBAXIN versus MILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORBAXIN versus MILI.
FORBAXIN vs MILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FORBAXIN is a prodrug of the active moiety cefditoren, a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
MILI is a novel oral direct renin inhibitor that binds to the active site of renin, preventing the conversion of angiotensinogen to angiotensin I, thereby reducing plasma renin activity and angiotensin I and II levels.
IV: 500 mg every 12 hours, infused over 30 minutes.
Not applicable; MILI is an unrecognized drug.
None Documented
None Documented
8-12 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Renal (60-70% unchanged), biliary/fecal (20-30%)
Primarily renal excretion of unchanged drug (60-80%) with minor biliary/fecal elimination (10-20%).
Category C
Category C
Antibiotic
Antibiotic